A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

NCT02279719 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: BBI608
DRUG: BBI503
DRUG: Sorafenib

Sponsor

Sumitomo Pharma America, Inc.